MetLife Investment Management’s Anavex Life Sciences AVXL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $109K | Sell |
35,430
-290
| -0.8% | -$1.26K | ﹤0.01% | 2500 |
|
|
2025
Q4 | $127K | Sell |
35,720
-8,885
| -20% | -$54.4K | ﹤0.01% | 2488 |
|
|
2025
Q3 | $397K | Buy |
+44,605
| New | +$452K | ﹤0.01% | 1920 |
|
|
2025
Q2 | – | Sell |
-45,343
| Closed | -$389K | – | 2815 |
|
|
2025
Q1 | $389K | Sell |
45,343
-834
| -2% | -$7.88K | ﹤0.01% | 1846 |
|
|
2024
Q4 | $496K | Buy |
46,177
+5,816
| +14% | +$44.7K | ﹤0.01% | 1803 |
|
|
2024
Q3 | $229K | Hold |
40,361
| – | – | ﹤0.01% | 2217 |
|
|
2024
Q2 | $170K | Buy |
40,361
+12,095
| +43% | +$48.9K | ﹤0.01% | 2347 |
|
|
2024
Q1 | $144K | Sell |
28,266
-7,983
| -22% | -$44.9K | ﹤0.01% | 2364 |
|
|
2023
Q4 | $337K | Hold |
36,249
| – | – | ﹤0.01% | 1922 |
|
|
2023
Q3 | $237K | Hold |
36,249
| – | – | ﹤0.01% | 2107 |
|
|
2023
Q2 | $295K | Hold |
36,249
| – | – | ﹤0.01% | 2025 |
|
|
2023
Q1 | $311K | Hold |
36,249
| – | – | ﹤0.01% | 1935 |
|
|
2022
Q4 | $336K | Hold |
36,249
| – | – | ﹤0.01% | 1895 |
|
|
2022
Q3 | $374K | Buy |
36,249
+2,553
| +8% | +$26.9K | ﹤0.01% | 1847 |
|
|
2022
Q2 | $337K | Sell |
33,696
-3,219
| -9% | -$30.5K | ﹤0.01% | 1942 |
|
|
2022
Q1 | $454K | Buy |
36,915
+13,623
| +58% | +$168K | ﹤0.01% | 1833 |
|
|
2021
Q4 | $404K | Hold |
23,292
| – | – | ﹤0.01% | 1626 |
|
|
2021
Q3 | $418K | Hold |
23,292
| – | – | ﹤0.01% | 1630 |
|
|
2021
Q2 | $532K | Hold |
23,292
| – | – | ﹤0.01% | 1534 |
|
|
2021
Q1 | $348K | Buy |
23,292
+15,192
| +188% | +$166K | ﹤0.01% | 1731 |
|
|
2020
Q4 | $43.7K | Buy |
8,100
+3,381
| +72% | +$17.8K | ﹤0.01% | 2256 |
|
|
2020
Q3 | $21.5K | Sell |
4,719
-21,037
| -82% | -$90.5K | ﹤0.01% | 2283 |
|
|
2020
Q2 | $127K | Buy |
+25,756
| New | +$97.3K | ﹤0.01% | 2145 |
|
Other funds holding AVXL
VCM
SF
VPM